Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy-Targeted Therapy Posts on Medivizor

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Posted by on Jun 13, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment.   This study concluded that TFR is safe and durable in these patients.   Some background The...

Read More

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Posted by on Apr 21, 2021 in Leukemia | 0 comments

In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...

Read More

Managing the side effects of ibrutinib treatment 

Managing the side effects of ibrutinib treatment 

Posted by on Jun 14, 2020 in Leukemia | 0 comments

In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment.  Some background Ibrutinib is a...

Read More

The effects of hydroxychloroquine and imatinib on treatment outcomes in patients with chronic myeloid leukemia

Posted by on Apr 12, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the combined effects of imatinib (IM; Gleevec) and hydroxychloroquine (HCQ; Plaquenil) in patients with chronic-phase chronic myeloid leukemia (CP-CML) and residual leukemic stem cells. The authors found that this combination safely and moderately improved treatment outcomes in such patients compared to IM alone. Some...

Read More

The outcomes of stem cell transplant for patients with blast crisis chronic myeloid leukemia pretreated with tyrosine kinase inhibitors

Posted by on Aug 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of stem cell transplant in patients with blast crisis chronic myeloid leukemia who were pre-treated with tyrosine kinase inhibitors.   This study concluded that the survival of these patients was strongly dependent on pretransplant remission status.  Some background...

Read More

Outcomes od BCR-ABL mutated chronic myeloid leukemia patients who have failed tyrosine kinase inhibitors

Posted by on Aug 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the frequency of BCR-ABL kinase domain mutation detection and its prognostic significance in patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs).  This study concluded that early mutation detection and use of 2nd and...

Read More

Heart-related side effects of tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Mar 31, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of cardiovascular (heart and blood vessel) side effects in patients with chronic myeloid leukemia who were treated with tyrosine kinase inhibitors. This study concluded that these side effects were more frequent in this group of patients. Some background Cardiovascular events (CVE) have been...

Read More

Symptom burden for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Posted by on Oct 30, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the symptom burden on patients with chronic phase chronic myeloid leukemia (CP-CML) who were treated with second or third generation tyrosine kinase inhibitors. This study concluded that the side effects of this treatment may affect the quality of life for these patients. Some background Chronic myeloid...

Read More

Evaluating nilotinib as a consolidation therapy for patients with chronic myeloid leukemia

Posted by on Sep 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...

Read More